Lu Qi-Zhong, Li Xiang, Ouyang Jun, Li Jin-Quan, Chen Gang
Department Department of Urology and Neurosurgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China.
Med Gas Res. 2019 Jan 9;8(4):167-171. doi: 10.4103/2045-9912.248268. eCollection 2018 Oct-Dec.
Hyperbaric oxygen therapy (HBOT) has been used as an adjuvant treatment for multiple pathological states, which involves hypoxic conditions. Over the past 50 years, HBOT has been recommended and used in a wide variety of medical conditions, clinically in the treatment of ischemic or nonhealing wounds and radiation-injured tissue, and in the treatment of malignancy. The mechanism of this treatment is providing oxygen under pressure which is higher than the atmosphere thus increasing tissue oxygen concentration. When cells get enough oxygen in the microenvironment, they become active and replicate effectively. Prostate cancer is the second most common cancer and the fifth leading cause of cancer death among male around the world. It is estimated that more than 29,000 men died from metastatic prostate cancer in 2014. With the development of the prostate-specific antigen-based screening technology, prostate cancer incidence has increased markedly over time. According to the survey, the morbidity and mortality of prostate cancer have surpassed bladder cancer and renal carcinoma, becoming the most common cancer in urology in Chinese adults. Nowadays, the main solution to deal with prostate cancer is still the surgical ways, including laparoscopic radical prostatectomy and robot-assisted radical prostatectomy. Nevertheless, the complications of the surgical treatment have not been completely avoided. HBOT has gained great clinical recognition over the decade. It has been demonstrated that HBOT has considerable effects on carcinoma, especially on decreasing complications and improving mortality. So, it is important to combine the HBOT with patients who suffer from prostate cancer. This review illuminates the effect and underlying mechanism of the HBOT in prostate cancer for further clinical application.
高压氧疗法（HBOT）已被用作多种病理状态的辅助治疗，这些病理状态涉及缺氧情况。在过去50年中，HBOT已被推荐并应用于多种医疗状况，临床上用于治疗缺血性或不愈合伤口以及放射性损伤组织，还用于治疗恶性肿瘤。这种治疗的机制是在高于大气压力的情况下提供氧气，从而提高组织氧浓度。当细胞在微环境中获得足够的氧气时，它们会变得活跃并有效复制。前列腺癌是全球男性中第二常见的癌症，也是癌症死亡的第五大主要原因。据估计，2014年有超过29000名男性死于转移性前列腺癌。随着基于前列腺特异性抗原的筛查技术的发展，前列腺癌的发病率随时间显著增加。据调查，前列腺癌的发病率和死亡率已超过膀胱癌和肾癌，成为中国成年人泌尿外科中最常见的癌症。如今，治疗前列腺癌的主要方法仍然是手术方式，包括腹腔镜前列腺癌根治术和机器人辅助前列腺癌根治术。然而，手术治疗的并发症尚未完全避免。在过去十年中，HBOT已获得了极大的临床认可。已经证明，HBOT对癌症有显著影响，特别是在减少并发症和提高生存率方面。因此，将HBOT与前列腺癌患者相结合很重要。这篇综述阐述了HBOT在前列腺癌中的作用及潜在机制，以供进一步临床应用。
